37359413|t|Adverse events with quetiapine and clarithromycin coprescription: A population-based retrospective cohort study.
37359413|a|Background and Aims: Quetiapine is an atypical antipsychotic predominantly metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme. We studied the risk of adverse events following coprescription of clarithromycin (a strong CYP3A4 inhibitor) versus azithromycin (not a CYP3A4 inhibitor) in quetiapine users. Materials and Methods: This was a population-based retrospective cohort study from 2004 to 2020 in Ontario, Canada in adult quetiapine users newly co-prescribed clarithromycin (n = 16,909) or azithromycin (n = 25,267). The primary outcome was the composite of hospital encounters with encephalopathy (defined as a diagnosis of delirium, disorientation, transient alteration of awareness, transient ischemic attack, or unspecified dementia), a fall, or a fracture within 30 days of new coprescription. Secondary outcomes were individual components of the composite outcome, hospital encounter with computed tomography (CT) head scan, and all-cause mortality. Results: Coprescription of clarithromycin versus azithromycin with quetiapine was associated with a higher risk of the primary composite outcome (365 of 16,909 clarithromycin users [2.2%] vs. 309 of 16,929 azithromycin users [1.8%]; absolute risk increase, 0.34% [95% confidence interval, CI, 0.04-0.63]; relative risk [RR], 1.19 [95% CI, 1.02-1.38]). This was primarily driven by an increase in fragility fractures (78 of 16,909 clarithromycin users [0.5%] vs. 45 of 16,923 azithromycin users [0.3%]; absolute risk increase, 0.20% [95% CI, 0.07-0.32]; RR, 1.74 [95% CI, 1.21-2.52]). Hospital encounters with a CT head scan were higher in clarithromycin users (220 of 16,909 [1.3%] vs. 175 of 16,923 azithromycin users [1.0%]; absolute risk increase, 0.27% [95% CI, 0.04-0.50]; RR, 1.26 [95% CI, 1.04-1.54]), but there was no difference in hospital encounters with encephalopathy, falls, or all-cause mortality between macrolide groups. Conclusion: Among adults taking quetiapine, concurrent use of clarithromycin compared with azithromycin was associated with a small but statistically greater 30-day risk of a hospital encounter for encephalopathy, falls, or fracture, which was predominantly related to a higher rate of fragility fractures.
37359413	20	30	quetiapine	Chemical	MESH:D000069348
37359413	35	49	clarithromycin	Chemical	MESH:D017291
37359413	134	144	Quetiapine	Chemical	MESH:D000069348
37359413	207	226	cytochrome P450 3A4	Gene	1576
37359413	228	234	CYP3A4	Gene	1576
37359413	310	324	clarithromycin	Chemical	MESH:D017291
37359413	335	341	CYP3A4	Gene	1576
37359413	360	372	azithromycin	Chemical	MESH:D017963
37359413	380	386	CYP3A4	Gene	1576
37359413	401	411	quetiapine	Chemical	MESH:D000069348
37359413	543	553	quetiapine	Chemical	MESH:D000069348
37359413	580	594	clarithromycin	Chemical	MESH:D017291
37359413	611	623	azithromycin	Chemical	MESH:D017963
37359413	704	718	encephalopathy	Disease	MESH:D001927
37359413	746	754	delirium	Disease	MESH:D003693
37359413	807	832	transient ischemic attack	Disease	MESH:D002546
37359413	849	857	dementia	Disease	MESH:D003704
37359413	873	881	fracture	Disease	MESH:D050723
37359413	1104	1118	clarithromycin	Chemical	MESH:D017291
37359413	1126	1138	azithromycin	Chemical	MESH:D017963
37359413	1144	1154	quetiapine	Chemical	MESH:D000069348
37359413	1237	1251	clarithromycin	Chemical	MESH:D017291
37359413	1283	1295	azithromycin	Chemical	MESH:D017963
37359413	1473	1492	fragility fractures	Disease	MESH:D005600
37359413	1507	1521	clarithromycin	Chemical	MESH:D017291
37359413	1552	1564	azithromycin	Chemical	MESH:D017963
37359413	1716	1730	clarithromycin	Chemical	MESH:D017291
37359413	1777	1789	azithromycin	Chemical	MESH:D017963
37359413	1942	1956	encephalopathy	Disease	MESH:D001927
37359413	1958	1963	falls	Disease	MESH:C537863
37359413	1996	2005	macrolide	Chemical	MESH:D018942
37359413	2046	2056	quetiapine	Chemical	MESH:D000069348
37359413	2076	2090	clarithromycin	Chemical	MESH:D017291
37359413	2105	2117	azithromycin	Chemical	MESH:D017963
37359413	2212	2226	encephalopathy	Disease	MESH:D001927
37359413	2228	2233	falls	Disease	MESH:C537863
37359413	2238	2246	fracture	Disease	MESH:D050723
37359413	2300	2319	fragility fractures	Disease	MESH:D005600
37359413	Association	MESH:D000069348	MESH:D017291
37359413	Positive_Correlation	MESH:D017291	MESH:C537863
37359413	Positive_Correlation	MESH:D017963	MESH:D001927
37359413	Association	MESH:D000069348	1576
37359413	Association	MESH:D000069348	MESH:D018942
37359413	Comparison	MESH:D017291	MESH:D017963
37359413	Positive_Correlation	MESH:D017963	MESH:D002546
37359413	Positive_Correlation	MESH:D017963	MESH:D003693
37359413	Positive_Correlation	MESH:D017291	MESH:D002546
37359413	Positive_Correlation	MESH:D017291	MESH:D050723
37359413	Association	MESH:D000069348	MESH:D017963
37359413	Positive_Correlation	MESH:D017291	MESH:D003693
37359413	Positive_Correlation	MESH:D000069348	MESH:D001927
37359413	Positive_Correlation	MESH:D017291	MESH:D005600
37359413	Negative_Correlation	MESH:D017291	1576
37359413	Positive_Correlation	MESH:D017963	MESH:D005600
37359413	Positive_Correlation	MESH:D017291	MESH:D001927
37359413	Association	MESH:D018942	MESH:C537863

